FAQs
During a hereditary angioedema (HAE) attack, your body produces too much of a protein called bradykinin.1–5 In large quantities, this protein causes fluid in the blood vessels to leak into the surrounding area, causing painful and sometimes disfiguring swelling.1–6 SAJAZIR works by preventing bradykinin from attaching to receptors found on the lining of blood vessels, which limits their activity and reduces the symptoms of the HAE attack.6
Talk to your doctor and ask them to download, complete and fax an enrollment form and write your prescription for SAJAZIR (specifying the brand name), including any special instructions required by your state (e.g. “dispense as written”). The rules for dispensing branded products vary by state and your doctor should be aware of precisely what is needed to complete your prescription and enrollment form.
Let your doctor know about any other medical conditions you have, or any other medication you are taking.6 SAJAZIR has not been evaluated in pregnant or breastfeeding women, so if you are pregnant or planning to be, or breastfeeding or planning to, you should tell your doctor.6
Before you start treatment with SAJAZIR, you have the option to receive a training pack and thorough 1-to-1 training on how to administer SAJAZIR.6 One of our registered product support nurses will take you through the process step-by-step until you are fully confident and capable to administer it on your own in the future.
As soon as you recognize the symptoms of a hereditary angioedema (HAE) attack, you should administer SAJAZIR.6 However, if you still have symptoms after your SAJAZIR injection, or they return, additional SAJAZIR doses can be taken at least 6 hours apart. You should not use more than 3 doses in a 24-hour period.6
References
- Maurer M, et al. Allergy. 2018;73(8):1575–1596.
- Zuraw BL, et al. J Allergy Clin Immunol Pract. 2013;1(5):458–467.
- El-Shanawany T. Hereditary Angioedema. British Society for Immunology. https://www.immunology.org/public-information/bitesized-immunology/immune-dysfunction/hereditary-angioedema (accessed October 2021).
- Ghazi A, Grant JA. Biologics. 2013;7:103–113.
- Lumry W, et al. Journal of Infusion Nursing, 2020;43(3):134–145.
- SAJAZIR™ (icatibant) Injection. Prescribing Information. Cycle Pharmaceuticals Limited.